Cas:23244-58-8 Methyl phthalimidoacetate manufacturer & supplier

Chemical Name:Methyl phthalimidoacetate

CAS.NO:23244-58-8

Synonyms:2H-Isoindole-2-acetic acid, 1,3-dihydro-1,3-dioxo-, methyl ester;Methyl (1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)acetate;Methyl phthalimidoacetate;phthalimidoacetic acid methyl ester;N-Phthaloylglycine methyl ester;Methyl phthalimid-1-ylacetate;Methyl 2-phthalimidoacetate

Molecular Formula:C₁₁H₉NO₄

Molecular Weight:219.193

HS Code:2925190090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:345.7±25.0 °C at 760 mmHg

Density:1.4±0.1 g/cm3

Index of Refraction:1.581

PSA:63.68000

Exact Mass:219.053162

LogP:1.66

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2H-Isoindole-2-acetic acid, 1,3-dihydro-1,3-dioxo-, methyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Methyl 2-phthalimidoacetate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2H-Isoindole-2-acetic acid, 1,3-dihydro-1,3-dioxo-, methyl ester Use and application,Methyl (1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)acetate technical grade,usp/ep/jp grade.

Related News: Retrogenix��s extensive library of human proteins make it uniquely placed for assessing candidate antibodies for target binding. Methyl phthalimidoacetate manufacturer The increase in environmental protection pressure has also increased the environmental protection expenditure of pharmaceutical manufacturing companies, which forced some small production capacity to withdraw from the market, increased industry concentration, and brought certain opportunities for API manufacturers. Methyl phthalimidoacetate supplier For example, there are concerns that PFAS’ effect on the thyroid could lead to thyroid cancer, van Gerwen said. Methyl phthalimidoacetate vendor The Darzalex-Rd regimen got its FDA go-ahead in transplant-ineligible patients in 2019 based on data from the same phase 3 MAIA trial showing it could pare down the risk of disease progression or death by 44% after a median follow-up of 28 months. Now, after 56.2 months of follow-up, over half of Darzalex patients were still alive without their disease worsening, a showing that’s again “unprecedented” for a front-line myeloma treatment, Tendler said. Methyl phthalimidoacetate factory Retrogenix��s extensive library of human proteins make it uniquely placed for assessing candidate antibodies for target binding.